



# SIDDS 2023

Seoul International Digestive Disease Symposium 2023

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 8-9, 2023 Hybrid congress



<b>Name</b>	Carlo Fallone
<b>Affiliation</b>	McGill University
<b>Country</b>	Canada
<b>Major Field</b>	Gastroenterology

## Educational Background

Medical School

1984-1988 MD, CM: McGill University, Montreal, Canada

Residency

1988-1991 Internal Medicine: Montreal General Hospital, McGill, Montreal, Canada

1991-1993 Gastroenterology: McGill University Hospitals, Montreal, Canada

Research Fellowships

1993-1994 Gastric cyto-protection/*Helicobacter pylori*, Queens University, Kingston, Canada

1994-1995 *Helicobacter pylori*, McGill University, Montreal, Canada

## Professional Experience

Current appointment:

1994-present Gastroenterologist, McGill University Health Center, Montreal, Canada

2019-present Gastrointestinal Endoscopy Director, McGill University Health Center, Montreal, Canada

2002-present Associate Professor, McGill University, Montreal, Canada

Previous appointments:

1997-1999 Assistant site director, Gastroenterology, Royal Victoria Hospital, Montreal Canada

2001-2007 Site Director, Gastroenterology, Royal Victoria Hospital, Montreal, Canada

2008-2021 Chair, Association of Physicians, Medicine, McGill University Health Center, Montreal

## Other Experience and Professional Memberships

•Leadership roles in Professional Associations:

- Canadian *Helicobacter* Study Group

1997-2001 Treasurer

2001-present Vice President

- Quebec Gastroenterology Association

2005-2011 Executive board member

- Canadian Association of Gastroenterology

2005-2009 Vice President Finance

2010-2013 Vice President Administration

2016-2019 Executive Vice President

- Canadian Digestive Health Foundation

2016-2019 Executive board member,

•Organization of meetings:

-1997-2015 Canadian *Helicobacter* Study Group Consensus Conferences

Organized 10 consensus conferences on various topics on *H pylori*



# SIDDS 2023

Seoul International Digestive Disease Symposium 2023

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 8-9, 2023 Hybrid congress



-Canadian Digestive Diseases Week 2007

Was part of the Implementation Committee for this meeting

-2005 World Congress of Gastroenterology

Was part of the Scientific Program Committee

•Editorial Boards:

2015-2016 Canadian Journal of Gastroenterology

2017-2022 Journal of the Canadian Association of Gastroenterology

•Other Relevant Contributions:

Participated in the H. pylori Maastricht VI- Florence European Helicobacter and Microbiota Study Group

consensus conference in 2021

## Main Scientific Publications

1. Barkun AN, Crott R, Fallone CA, Kennedy WA, Lachaine J, Levinton C, Armstrong D, Chiba N, Thomson A, Veldhuyzen van Zanten S, Sinclair P, Escobedo S, Chakakraborty B, Smyth S, White R, Kalra H, Nevin K. A one-year economic evaluation of six alternative strategies for the management of uninvestigated upper gastrointestinal symptoms in Canadian primary care. *Can J Gastroenterol* 2010; 24: 489-498.
2. Jones NL, Chiba N, Fallone C, Thomson A, Hunt R, Jacobson K, Goodman K, on behalf of Canadian *Helicobacter* study group participants. *Helicobacter pylori* in First Nations and recent immigrant populations in Canada. *Can J Gastroenterol* 2012; 26: 97-103.
3. Fallone CA, Barkun AN, Szilagyi A, Herba KM, Sewitch M, Martel M, Fallone SS. Prolonged treatment duration is required for successful *Helicobacter pylori* eradication with proton pump inhibitor triple therapy in Canada. *Can J Gastroenterol* 2013; 27: 397-402.
4. Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P. Optimum duration of regimens for *Helicobacter pylori* eradication (Review). *Cochrane Database Systematic Reviews* 2013Dec; Issue12:CD008337. doi: 10.1002/14651858.CD008337. p. 1-420.
5. Chen Y-I, and Fallone CA. A 14-day course of triple therapy is superior to a 10-day course for the eradication of *Helicobacter pylori*: A Canadian study conducted in a “real world” setting. *Can J Gastroenterol & Hepatol* 2015; 29: e7-e10.
6. Shaikh T, and Fallone CA. Effectiveness of second through sixth line salvage *Helicobacter pylori* treatment: Bismuth Quadruple therapy is almost always a reasonable choice. *Can J Gastroenterol & Hepatol* 2016; doi 10.1155/2016/7321574.
7. Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, Fischbach L, Bazzoli F,



# SIDDS 2023

Seoul International Digestive Disease Symposium 2023

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 8-9, 2023 Hybrid congress



- Gisbert JP. Sequential versus standard triple first-line therapy for *Helicobacter pylori* eradication (Review). Cochrane Database of Systematic Reviews 2016 (June); Issue 6: Art. No. CD009034. doi:10.1002/14651858.CD009034. p.1-148.
8. Fallone CA, Chiba N, Veldhuyzen van Zanten S, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, and Marshall JK. The Toronto Consensus for the Treatment of *Helicobacter pylori* Infection in Adults. *Gastroenterology* 2016; 151:51-69. doi:10.1053/j.gastro.2016.04.006.
9. Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent *H. pylori* treatment guidelines in a time of increasing antibiotic resistance. *Gastroenterology* 2019; 157: 44-53. doi:https://doi.org/10.1053/j.gastro.2019.04.011
10. Fallone CA. The Current Role of Vonoprazan in *Helicobacter pylori* Treatment. *Gastroenterology* 2022; 163: 572-574. DOI: https://doi.org/10.1053/j.gastro.2022.06.076